MARKET

PGEN

PGEN

Precigen Inc
NASDAQ
1.415
+0.015
+1.07%
Opening 13:26 04/26 EDT
OPEN
1.400
PREV CLOSE
1.400
HIGH
1.430
LOW
1.390
VOLUME
245.16K
TURNOVER
0
52 WEEK HIGH
1.880
52 WEEK LOW
0.8354
MARKET CAP
352.22M
P/E (TTM)
-3.6079
1D
5D
1M
3M
1Y
5Y
*Correct: Actym Therapeutics, Not AnaptysBio, Appoints Thomas Smart as CEO
Dow Jones · 2d ago
*AnaptysBio Names Thomas Smart as CEO >ANAB
Dow Jones · 2d ago
Press Release: Actym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics Appoints Thomas Smart as CEO of a new drug modality to treat solid tumors. Mr. Smart has 25 years of experience in senior management and executive roles across the biopharmaceutical industry. Actym's lead candidate, ACTM-838, will enter clinical evaluation later this year.
Dow Jones · 2d ago
Weekly Report: what happened at PGEN last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at PGEN last week (0408-0412)?
Weekly Report · 04/15 09:23
Weekly Report: what happened at PGEN last week (0401-0405)?
Weekly Report · 04/08 09:25
AquaBounty Technologies Inc reports results for the quarter ended in December - Earnings Summary
AquaBounty Technologies Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $2.19 per share. Revenue rose 22.8% to $554.00 thousand from the same quarter last year. Wall Street expected the company to report a profit of $1.53 per share in the quarter.
Reuters · 04/02 14:21
Weekly Report: what happened at PGEN last week (0325-0329)?
Weekly Report · 04/01 09:24
More
About PGEN
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Webull offers Precigen Inc stock information, including NASDAQ: PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.